Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8374148 | 0.89 | TAAR1 (0.43) | VNN1MAPTSMN1; SMN2CYP11B2PDE4B | |
| SCHEMBL4572154 | 0.89 | MAPT (0.44) | MAPTGAASMN1; SMN2NOS3NOS2 | |
| SCHEMBL21929958 | 0.85 | VNN1 (0.41) | VNN1MAPTGAANOS3NOS2 | |
| SCHEMBL21930188 | 0.85 | VNN1 (0.41) | VNN1MAPTGAANOS3NOS2 | |
| SCHEMBL12085750 | 0.85 | VNN1 (0.41) | VNN1MAPTGAANOS3NOS2 | |
| SCHEMBL3008049 | 0.85 | LIPG (0.46) | MAPTGAACYP11B2THRBEPHX2 | |
| SCHEMBL12001420 | 0.84 | CHRNB2 (0.43) | VNN1MAPTGAASMN1; SMN2NOS3 | |
| SCHEMBL25629786 | 0.84 | PIK3CD (0.45) | VNN1PIK3CDEPHX2ALDH1A1 | |
| SCHEMBL21165830 | 0.82 | VNN1 (0.42) | VNN1GAATHRBATML3MBTL1 | |
| SCHEMBL12800957 | 0.82 | VNN1 (0.40) | VNN1MAPTGAATHRBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106146375-A | The synthetic method of medicine intermediate 1-acetyl-4-(2-ethoxy) pyrrolidines | 无锡乾浩生物医药有限公司 | 2016-11-23 | — | — | CN | claimed |
| US-11667624-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-10780073-B2 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA INC. (US) | 2020-09-22 | — | — | US | disclosed |
| CN-106146375-A | The synthetic method of medicine intermediate 1-acetyl-4-(2-ethoxy) pyrrolidines | 无锡乾浩生物医药有限公司 | 2016-11-23 | — | — | CN | disclosed |
| CN-106146375-A | The synthetic method of medicine intermediate 1-acetyl-4-(2-ethoxy) pyrrolidines | 无锡乾浩生物医药有限公司 | 2016-11-23 | — | — | CN | disclosed |
| CN-106146375-A | The synthetic method of medicine intermediate 1-acetyl-4-(2-ethoxy) pyrrolidines | 无锡乾浩生物医药有限公司 | 2016-11-23 | — | — | CN | disclosed |
| WO-2011046970-A1 | AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON | MYREXIS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667624-B2 | Indole compounds as androgen receptor modulators | AR, FSHR, ADRB3 | VNN1 3786/4885MAPT 682/4885GAA 2539/4885 |
| US-10780073-B2 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ERBB4, ERBB2, ERBB3 | VNN1 2736/4885MAPT 4303/4885GAA 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.